What you believe and what you value as an organization matters. Discover the DNA of our firm.
Get to know our teams and the stories of select staff members who share why they choose to work at Sands Capital.
Read about some of the latest events, partnerships, and business highlights from Sands Capital.
Changing market and geopolitical environments are part of the equation for long-term investors. As active investors, we are prepared to manage through trying times.
Papercup’s proprietary AI dubbing solutions provide high-quality, inexpensive voiceover and video localization.
Executive Managing Director and Sr. Portfolio Manager Brian Christiansen discusses the importance of candor and collaboration in a culture that promotes long-term thinking.
Recruit Holdings is transforming the world of work through wage transparency and providing life-changing opportunities for immigrants and refugees.
Our philosophy is rooted in the belief that, over time, stock prices will reflect the earnings power and growth of the underlying businesses.
Our second annual stewardship report reflects our commitment to provide clients and other key stakeholders with transparency into our initiatives, actions, and the progress we made in 2022.
Our newest strategy takes an unconstrained approach to seeking the best growth businesses outside of the U.S.
Sands Capital invests in innovative businesses across all stages of the growth spectrum
Director of Technical Research
2022
Farcast Biosciences (2017-2020)
Bangalore, India | Director R&D, Intellectual Property
General Electric (2010 - 2017)
Bangalore, India | Lead Intellectual Property Professional
Brigham & Women’s Hospital, Harvard-MIT Division of Health Science and Technology (2007 - 2010)
Cambridge, MA | Post-doctoral fellow
Indian Institute of Science (2002-2007)
PhD | Organic Chemistry
Indian Institute of Science (1999 - 2002)
Master of Science | Chemical Sciences
Padmaparna joined Sands Capital in 2022 as the Director of Technical Research, reporting to Parker Cassidy. Prior to that, Padmaparna spent 12 years in large multi-national and startup companies, working across different life sciences tools and diagnostic programs. In those roles, she has led the creation of patent portfolios and performed technology and intellectual property analysis to identify R&D and inorganic growth opportunities. The work contributed to initiation and shaping of various internal research programs, and led to some key collaborations/acquisitions. Padmaparna did her PhD from Indian Institute of Science (India) in Bioorganic Chemistry and her post-doctoral research in Harvard Medical School/Brigham & Women’s Hospital in the area of targeted drug delivery in cancer.